Susan J. Aluise

Susan J. Aluise

Susan J. Aluise is president and executive editor of National News Syndicate, a Washington, D.C.-based news organization focused on global business, national security, information technology, transportation and financial services. Prior to forming the company in January 1996, she spent a decade at Potomac, Md.-based Phillips Business Information — the last six years as editorial director. She has launched 31 subscription-based news publications and websites in the Aviation, Financial Services, Defense, Information Technology and Telecom industries, including Aviation Today, World Airport Week, Credit Risk Management Report and Electronic Commerce Insider. In a journalism career spanning more than 30 years, Susan has covered six U.S. presidents and 15 Congresses for a variety of U.S. and global news organizations. She also has covered several international political and economic summits and was honored by a national journalism foundation for excellence in news and analysis following the 9/11 terror attacks.

Recent Articles

EMC Stock – Is the Best Path Forward a Marriage or a Breakup?

Don't get jazzed about talk of a potential EMC breakup. Thanks to “Federation Strategy,” EMC could be far more valuable than the sum of its parts.

Space Taxi Win Won’t Boost Boeing Stock

NASA’s contract award generates a lot of buzz and conjures up Star Trek dreams to “boldly go where no man has gone before.” But manned space flight has always been less about money and more about boundless imagination and international prestige.

3 Reasons FedEx Stock Is Still a Buy After Earnings Beat

After posting a comfortable earnings beat, thanks to growth across all business segments, FedEx stock is looking like a buy

ORCL – 3 Things to Watch for in Oracle Earnings

Here are three things to watch in Oracle earnings if you’re evaluating whether ORCL stock deserves a place in your portfolio now.

3 Hot Ways to Play the Biotechnology Bonanza

Gaining exposure to the biotechnology sector makes sense for most investors. The biggest question is how you play the biotech boom.